糖尿病性ケトアシドーシス（DKA）の世界市場レポート 2025年

糖尿病性ケトアシドーシス（DKA）市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）8.5％で43億7,000万米ドルに成長します。予測期間の成長は、インスリン送達システムの進歩、持続的グルコースモニタリングの採用拡大、糖尿病関連合併症に対する意識の高まり、糖尿病管理のための遠隔医療の拡大、ヘルスケア支出の増加が牽引すると予想されます。この期間の主な動向には、糖尿病治療における人工知能の統合、クローズドループインスリン送達システムの開発、個別化医療、最先端技術、革新的治療などがあります。

肥満の有病率の上昇が糖尿病性ケトアシドーシス（DKA）市場の拡大に寄与しています。肥満は、体脂肪の過剰な蓄積を特徴とする病状であり、健康に悪影響を及ぼし、さまざまな疾患のリスクを高める可能性があります。肥満率の増加は、加工食品、砂糖、脂肪の多い不健康な食事、身体活動が制限された座りがちなライフスタイル、長時間のスクリーン利用、手頃な健康食品やヘルスケアへのアクセス制限といった社会経済的課題など、いくつかの要因によってもたらされています。肥満は、インスリン抵抗性を促進し、2型糖尿病の開発につながることで、糖尿病性ケトアシドーシス（DKA）のリスクを高める。例えば、2024年3月、スイスに本部を置く政府間機関である世界保健機関（WHO）は、世界の約8人に1人が肥満の影響を受けていると報告しました。この中には25億人の成人（18歳以上）が含まれ、8億9,000万人が肥満と分類されています。成人のうち43％が太りすぎ、16％が肥満でした。さらに、5歳未満の太りすぎの子どもは3,700万人に達しました。その結果、肥満の蔓延が糖尿病性ケトアシドーシス市場の拡大を牽引しています。

糖尿病性ケトアシドーシス市場の主要企業は、早期発見を強化し、血糖値とケトン体レベルの管理を改善し、最終的に糖尿病患者のDKAエピソードの頻度と重症度を低減するために、持続グルコースモニタリングツールなどの先進技術の開発を優先しています。持続グルコースモニタリング（CGM）ツールは、グルコースレベルをリアルタイムで追跡するように設計された装置であり、糖尿病患者が血糖値を効果的にモニターし、調整することを可能にします。例えば、2022年6月、米国の医療機器会社であるアボット・ラボラトリーズは、グルコースとケトン体レベルの両方をリアルタイムで追跡できる革新的な持続グルコース・ケトン監視システムを発表しました。このシステムはグルコースとケトン体のモニタリングを統合し、患者の代謝状態を包括的に把握できます。両方の指標を同時に測定することで、糖尿病性ケトアシドーシス（DKA）のような潜在的な糖尿病合併症が重篤化する前の早期発見が容易になります。継続的なモニタリングのために設計されたこのシステムは、手動による検査を必要とせず、頻繁なデータ更新を提供し、ユーザーの利便性を高めています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界糖尿病性ケトアシドーシス（DKA） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の糖尿病性ケトアシドーシス（DKA）市場：成長率分析
• 世界の糖尿病性ケトアシドーシス（DKA）市場の実績：規模と成長, 2019-2024
• 世界の糖尿病性ケトアシドーシス（DKA）市場の予測：規模と成長, 2024-2029, 2034F
• 世界糖尿病性ケトアシドーシス（DKA）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の糖尿病性ケトアシドーシス（DKA）市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児糖尿病性ケトアシドーシス
• 成人糖尿病性ケトアシドーシス
• 世界の糖尿病性ケトアシドーシス（DKA）市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 体液補充
• 電解質補給
• インスリン療法
• 中間型インスリン
• 長時間作用型インスリン
• 世界の糖尿病性ケトアシドーシス（DKA）市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の糖尿病性ケトアシドーシス（DKA）市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オンラインチャンネル
• オフラインチャンネル
• 世界の糖尿病性ケトアシドーシス（DKA）市場：最終用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 外来診療センター
• 専門クリニック
• 世界の糖尿病性ケトアシドーシス（DKA）市場小児糖尿病性ケトアシドーシスの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 軽度の小児DKA
• 中等度の小児DKA
• 重症小児DKA
• 世界の糖尿病性ケトアシドーシス（DKA）市場成人糖尿病性ケトアシドーシスの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 軽度の成人DKA
• 中等度の成人DKA
• 重症成人DKA

第7章 地域別・国別分析

• 世界の糖尿病性ケトアシドーシス（DKA）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の糖尿病性ケトアシドーシス（DKA）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 糖尿病性ケトアシドーシス（DKA）市場：競合情勢
• 糖尿病性ケトアシドーシス（DKA）市場：企業プロファイル
  • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Roche Holding AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• B. Braun Medical Inc.
• Fresenius Kabi
• Merit Pharmaceutical
• Oramed Pharmaceuticals Inc.
• ICU Medical Inc.
• Tonghua Dongbao Pharmaceutical Co. Ltd.
• Wockhardt Ltd.
• Biocon Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 糖尿病性ケトアシドーシス（DKA）市場2029：新たな機会を提供する国
• 糖尿病性ケトアシドーシス（DKA）市場2029：新たな機会を提供するセグメント
• 糖尿病性ケトアシドーシス（DKA）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Diabetic ketoacidosis (DKA) is a serious complication of diabetes in which the body produces excessive blood acids known as ketones due to inadequate insulin levels. This condition can lead to dehydration, electrolyte imbalances, and potentially life-threatening complications. It is essential for diagnosing and managing severe metabolic imbalances in diabetic patients to prevent risks such as dehydration, organ failure, and coma.

The primary types of diabetic ketoacidosis (DKA) include pediatric diabetic ketoacidosis and adult diabetic ketoacidosis. Pediatric DKA occurs in children and adolescents with diabetes and is often triggered by insulin deficiency, infections, or other stress factors. Treatment options involve fluid replacement, electrolyte replenishment, and insulin therapy, including intermediate-acting and long-acting insulin. The available administration routes include oral, parenteral, and other methods. These treatments are distributed through various channels, both online and offline, and are utilized by multiple end users, such as hospitals, ambulatory care centers, and specialty clinics.

The diabetic ketoacidosis (DKA) market research report is one of a series of new reports from The Business Research Company that provides diabetic ketoacidosis (DKA) market statistics, including diabetic ketoacidosis (DKA) industry global market size, regional shares, competitors with diabetic ketoacidosis (DKA) market share, detailed diabetic ketoacidosis (DKA) market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic ketoacidosis (DKA) industry. This diabetic ketoacidosis (DKA) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diabetic ketoacidosis (DKA) market size has grown strongly in recent years. It will grow from $2.90 billion in 2024 to $3.16 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth during the historic period can be attributed to the rising prevalence of diabetes, delayed diagnosis of type 1 diabetes, poor adherence to insulin therapy, increasing obesity rates, and the lack of diabetes education programs.

The diabetic ketoacidosis (DKA) market size is expected to see strong growth in the next few years. It will grow to $4.37 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period is expected to be driven by advancements in insulin delivery systems, the increasing adoption of continuous glucose monitoring, greater awareness of diabetes-related complications, the expansion of telemedicine for diabetes management, and rising healthcare expenditures. Key trends during this period include the integration of artificial intelligence in diabetes care, the development of closed-loop insulin delivery systems, personalized medicine, cutting-edge technologies, and innovative therapies.

The rising prevalence of obesity is contributing to the expansion of the diabetic ketoacidosis (DKA) market. Obesity is a medical condition characterized by excessive accumulation of body fat, which can have adverse health effects and increase the risk of various diseases. The increase in obesity rates is driven by several factors, including unhealthy diets rich in processed foods, sugars, and fats, sedentary lifestyles with limited physical activity, prolonged screen time, and socioeconomic challenges such as limited access to affordable healthy food and healthcare. Obesity heightens the risk of diabetic ketoacidosis (DKA) by promoting insulin resistance and leading to the development of type 2 diabetes, which can result in poor blood sugar control and subsequent DKA episodes. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people worldwide were affected by obesity. This included 2.5 billion adults (aged 18 and older) who were overweight, with 890 million classified as obese. Among adults, 43% were overweight, and 16% were obese. Additionally, the number of overweight children under the age of five reached 37 million. Consequently, the growing prevalence of obesity is driving the expansion of the diabetic ketoacidosis market.

Leading companies in the diabetic ketoacidosis market are prioritizing the development of advanced technologies, such as continuous glucose monitoring tools, to enhance early detection, improve blood glucose and ketone level management, and ultimately reduce the frequency and severity of DKA episodes in individuals with diabetes. Continuous glucose monitoring (CGM) tools are devices designed to track glucose levels in real time, allowing individuals with diabetes to monitor and regulate their blood sugar levels effectively. For instance, in June 2022, Abbott Laboratories, a US-based medical device company, introduced an innovative continuous glucose-ketone monitoring system that enables real-time tracking of both glucose and ketone levels. This system integrates glucose and ketone monitoring, offering a comprehensive view of a patient's metabolic state. By measuring both metrics simultaneously, it facilitates the early detection of potential diabetic complications, such as diabetic ketoacidosis (DKA), before they become critical. Designed for continuous monitoring, the system provides frequent data updates without requiring manual testing, ensuring greater convenience for users.

In September 2023, Abbott Laboratories, a US-based medical device company, acquired Bigfoot Biomedical for an undisclosed amount. This acquisition strengthens Abbott's diabetic care portfolio, which already features the globally recognized FreeStyle Libre continuous glucose monitoring technology. Bigfoot Biomedical Inc. is a US-based company specializing in medical technology for diabetic care.

Major players in the diabetic ketoacidosis (DKA) market are Merck And Co. Inc., Pfizer Inc., Sanofi S.A., Bristol Myers Squibb, Novartis AG, Roche Holding AG, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., B. Braun Medical Inc., Fresenius Kabi, Merit Pharmaceutical, Oramed Pharmaceuticals Inc., ICU Medical Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., Wockhardt Ltd., Biocon Limited.

North America was the largest region in the diabetic ketoacidosis (DKA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diabetic ketoacidosis (DKA) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the diabetic ketoacidosis (DKA) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetic ketoacidosis (DKA) market includes revenues earned by entities by providing services such as blood glucose monitoring, ketone testing, and arterial blood gas analysis and related products such as blood glucose monitors, continuous glucose monitoring (CGM) devices, syringes, insulin pens, and insulin pumps. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diabetic Ketoacidosis (DKA) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diabetic ketoacidosis (dka) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diabetic ketoacidosis (dka) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The diabetic ketoacidosis (dka) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Pediatric Diabetic Ketoacidosis, Adult Diabetic Ketoacidosis
• 2) By Treatment Type: Fluid Replacement, Electrolyte Replacement, Insulin Therapy, Intermediate-Acting Insulin, Long-Acting Insulin
• 3) By Route of Administration: Oral, Parenteral, Other
• 4) By Distribution Channel: Online Channel, Offline Channel
• 5) By End Use: Hospitals, Ambulatory Care Center, Specialty Clinics
• Subsegments:
• 1) By Pediatric Diabetic Ketoacidosis: Mild Pediatric DKA; Moderate Pediatric DKA; Severe Pediatric DKA
• 2) By Adult Diabetic Ketoacidosis: Mild Adult DKA; Moderate Adult DKA; Severe Adult DKA
• Companies Mentioned: Merck And Co. Inc.; Pfizer Inc.; Sanofi S.A.; Bristol Myers Squibb; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Diabetic Ketoacidosis (DKA) Market Characteristics

3. Diabetic Ketoacidosis (DKA) Market Trends And Strategies

4. Diabetic Ketoacidosis (DKA) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Diabetic Ketoacidosis (DKA) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Diabetic Ketoacidosis (DKA) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Diabetic Ketoacidosis (DKA) Market Growth Rate Analysis
• 5.4. Global Diabetic Ketoacidosis (DKA) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Diabetic Ketoacidosis (DKA) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Diabetic Ketoacidosis (DKA) Total Addressable Market (TAM)

6. Diabetic Ketoacidosis (DKA) Market Segmentation

• 6.1. Global Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric Diabetic Ketoacidosis
• Adult Diabetic Ketoacidosis
• 6.2. Global Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fluid Replacement
• Electrolyte Replacement
• Insulin Therapy
• Intermediate-Acting Insulin
• Long-Acting Insulin
• 6.3. Global Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes of Administration
• 6.4. Global Diabetic Ketoacidosis (DKA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online Channel
• Offline Channel
• 6.5. Global Diabetic Ketoacidosis (DKA) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Care Center
• Specialty Clinics
• 6.6. Global Diabetic Ketoacidosis (DKA) Market, Sub-Segmentation Of Pediatric Diabetic Ketoacidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild Pediatric DKA
• Moderate Pediatric DKA
• Severe Pediatric DKA
• 6.7. Global Diabetic Ketoacidosis (DKA) Market, Sub-Segmentation Of Adult Diabetic Ketoacidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild Adult DKA
• Moderate Adult DKA
• Severe Adult DKA

7. Diabetic Ketoacidosis (DKA) Market Regional And Country Analysis

• 7.1. Global Diabetic Ketoacidosis (DKA) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Diabetic Ketoacidosis (DKA) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Diabetic Ketoacidosis (DKA) Market

• 8.1. Asia-Pacific Diabetic Ketoacidosis (DKA) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Diabetic Ketoacidosis (DKA) Market

• 9.1. China Diabetic Ketoacidosis (DKA) Market Overview
• 9.2. China Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Diabetic Ketoacidosis (DKA) Market

• 10.1. India Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Diabetic Ketoacidosis (DKA) Market

• 11.1. Japan Diabetic Ketoacidosis (DKA) Market Overview
• 11.2. Japan Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Diabetic Ketoacidosis (DKA) Market

• 12.1. Australia Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Diabetic Ketoacidosis (DKA) Market

• 13.1. Indonesia Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Diabetic Ketoacidosis (DKA) Market

• 14.1. South Korea Diabetic Ketoacidosis (DKA) Market Overview
• 14.2. South Korea Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Diabetic Ketoacidosis (DKA) Market

• 15.1. Western Europe Diabetic Ketoacidosis (DKA) Market Overview
• 15.2. Western Europe Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Diabetic Ketoacidosis (DKA) Market

• 16.1. UK Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Diabetic Ketoacidosis (DKA) Market

• 17.1. Germany Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Diabetic Ketoacidosis (DKA) Market

• 18.1. France Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Diabetic Ketoacidosis (DKA) Market

• 19.1. Italy Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Diabetic Ketoacidosis (DKA) Market

• 20.1. Spain Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Diabetic Ketoacidosis (DKA) Market

• 21.1. Eastern Europe Diabetic Ketoacidosis (DKA) Market Overview
• 21.2. Eastern Europe Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Diabetic Ketoacidosis (DKA) Market

• 22.1. Russia Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Diabetic Ketoacidosis (DKA) Market

• 23.1. North America Diabetic Ketoacidosis (DKA) Market Overview
• 23.2. North America Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Diabetic Ketoacidosis (DKA) Market

• 24.1. USA Diabetic Ketoacidosis (DKA) Market Overview
• 24.2. USA Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Diabetic Ketoacidosis (DKA) Market

• 25.1. Canada Diabetic Ketoacidosis (DKA) Market Overview
• 25.2. Canada Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Diabetic Ketoacidosis (DKA) Market

• 26.1. South America Diabetic Ketoacidosis (DKA) Market Overview
• 26.2. South America Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Diabetic Ketoacidosis (DKA) Market

• 27.1. Brazil Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Diabetic Ketoacidosis (DKA) Market

• 28.1. Middle East Diabetic Ketoacidosis (DKA) Market Overview
• 28.2. Middle East Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Diabetic Ketoacidosis (DKA) Market

• 29.1. Africa Diabetic Ketoacidosis (DKA) Market Overview
• 29.2. Africa Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Diabetic Ketoacidosis (DKA) Market Competitive Landscape And Company Profiles

• 30.1. Diabetic Ketoacidosis (DKA) Market Competitive Landscape
• 30.2. Diabetic Ketoacidosis (DKA) Market Company Profiles
  • 30.2.1. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Diabetic Ketoacidosis (DKA) Market Other Major And Innovative Companies

• 31.1. Roche Holding AG
• 31.2. GlaxoSmithKline plc
• 31.3. Eli Lilly and Company
• 31.4. Boehringer Ingelheim International GmbH
• 31.5. Novo Nordisk A/S
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Regeneron Pharmaceuticals Inc.
• 31.8. B. Braun Medical Inc.
• 31.9. Fresenius Kabi
• 31.10. Merit Pharmaceutical
• 31.11. Oramed Pharmaceuticals Inc.
• 31.12. ICU Medical Inc.
• 31.13. Tonghua Dongbao Pharmaceutical Co. Ltd.
• 31.14. Wockhardt Ltd.
• 31.15. Biocon Limited

32. Global Diabetic Ketoacidosis (DKA) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diabetic Ketoacidosis (DKA) Market

34. Recent Developments In The Diabetic Ketoacidosis (DKA) Market

35. Diabetic Ketoacidosis (DKA) Market High Potential Countries, Segments and Strategies

• 35.1 Diabetic Ketoacidosis (DKA) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Diabetic Ketoacidosis (DKA) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Diabetic Ketoacidosis (DKA) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer